drugset / Trial / NCT02321436

Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression

NCT02321436

Phase 4 Completed 42 enrolled Ipsen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate if early administration (i.e. within 12 weeks after stroke) of Dysport® 500 U injections may delay the appearance or the progression of upper limb symptomatic spasticity.

Timeline

Start
2014-12
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 500 iu Intramuscular